Currently, several therapeutic approaches such as PD-1/PD-L1 and CTLA-4 inhibitors have been appraised in attempts to combat aggressive cancers such as PDACs and MCCs, but have failed to produce durable responses in PDACs [74] and led to treatment resistance in some MCCs [75]. The gene discussed is CTLA4; the disease is cancer.